On June 25, 2026, the Compensation Committee approved retention bonuses for Eric Schlorff ($200,000) and Kevin Chung ($140,000). Payments vest in three equal installments on July 1, 2026, November 1, 2026, and March 1, 2027, contingent on continued employment. Each installment includes an additional 25% value in common stock under the 2022 Omnibus Incentive Plan. Formal agreements were executed on June 29, 2026. SeaStar Medical Holding Corporation operates in the medical device industry, developing technologies for the treatment of critical illness.

On June 10, 2026, SeaStar Medical Holding Corporation entered into a separation and release agreement with Mr. Green to resolve claims regarding his disputed not-for-cause termination. Under the terms of the mutual resolution, the company agreed to pay Mr. Green an amount exceeding what was previously disclosed in the August 19, 2025, filing. The company operates in the medical device industry, developing healthcare technologies.

On June 17, 2026, stockholders approved an amendment and restatement of the 2022 Omnibus Incentive Plan, increasing the number of authorized shares of common stock from 207,046 to 896,546. The company also elected John Neuman as a Class I director and ratified WithumSmith+Brown, PC as its independent registered public accounting firm for the fiscal year ending December 31, 2026. SeaStar Medical Holding Corporation operates in the medical technology industry and develops medical devices.